In this episode, Dr. Gandhi discusses topline results from several studies investigating weight gain and metabolic outcomes with different antiretroviral therapy (ART) regimens among patients with HIV, including lipid level changes, cardiovascular disease risk, diabetes risk, and metabolic syndrome risk. The overview will include analyses from: The ADVANCE trial comparing initial ART with DTG plus FTC/TAF, DTG plus FTC/TDF, or EFV/FTC/TDF, including an examination of the influence of CYP2B6 polymorphisms on weight change during EFV-based therapyThe NA-ACCORD studyEvaluating patients with virologic suppression who switched from non–integrase inhibitor (INSTI)–based regimens to INSTI-based regimensInvestigating the impact of initial ART regimen class on diabetes mellitus incidenceA study investigating the association between resting metabolic rate, oxygen consumption, and dietary intake changes and body weight/composition changes following ART initiationA study evaluating differences in postpartum weight change with DTG-based vs EFV-based ARTIn addition, Dr. Gandhi reviews new information on biomedical prevention of HIV infection, including results from several preclinical trials, a study investigating real-time urine-based testing for tenofovir levels, and the latest safety data from the phase III DISCOVER trial comparing FTC/TDF vs FTC/TAF for daily oral HIV pre-exposure prophylaxis (PrEP) among cis-gender men who have sex with men (MSM) and transgender women.Presenter:Monica Gandhi, MD, MPH Professor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineUniversity of California, San FranciscoMedical DirectorWard 86 HIV ClinicSan Francisco General HospitalSan Francisco, CaliforniaContent based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.Link to full program: https://bit.ly/3bBjeoD